Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany

The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.